In 2007, eculizumab was the first anti-C5 inhibitor to receive FDA approval for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), followed by atypical hemolytic uremic syndrome (aHUS) [292]. The gene discussed is C5; the disease is atypical hemolytic-uremic syndrome.